SEMLER SCIENTIFIC, INC. Financials Semler Scientific, Inc.
Equities
SMLR
US81684M1045
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.11 USD | +0.77% |
|
+1.48% | -41.05% |
| Mar. 05 | Transcript : Semler Scientific, Inc., Q4 2023 Earnings Call, Mar 05, 2024 | |
| Mar. 05 | Earnings Flash (SMLR) SEMLER SCIENTIFIC Posts Q4 Revenue $15.1M, vs. Street Est of $14.5M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 313.5 | 629.4 | 619.3 | 225.7 | 297.9 | 183.6 |
| Enterprise Value (EV) 1 | 313.5 | 629.4 | 582 | 225.7 | 297.9 | 183.6 |
| P/E ratio | 25.5 x | 54 x | 43.2 x | 18.4 x | 16.8 x | 7.68 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 9.57 x | 16.3 x | 11.7 x | 3.98 x | 4.37 x | 2.43 x |
| EV / Revenue | 9.57 x | 16.3 x | 11.7 x | 3.98 x | 4.37 x | 2.43 x |
| EV / EBITDA | 26.8 x | 37.5 x | 30.9 x | 12.7 x | 13 x | 5.63 x |
| EV / FCF | - | 43,843,339 x | 39,353,406 x | - | - | - |
| FCF Yield | - | 0% | 0% | - | - | - |
| Price to Book | - | 25.5 x | 16.4 x | - | - | - |
| Nbr of stocks (in thousands) | 6,531 | 6,696 | 6,758 | 6,840 | 6,727 | 7,031 |
| Reference price 2 | 48.00 | 94.00 | 91.65 | 33.00 | 44.29 | 26.11 |
| Announcement Date | 3/3/20 | 3/1/21 | 2/28/22 | 3/21/23 | 3/5/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 32.77 | 38.6 | 53.03 | 56.69 | 68.18 | 75.5 |
| EBITDA 1 | 11.7 | 16.79 | 20.07 | 17.79 | 22.86 | 32.6 |
| EBIT 1 | 10.71 | 15.96 | 19.44 | 17.2 | 22.26 | 31.9 |
| Operating Margin | 32.68% | 41.35% | 36.67% | 30.35% | 32.64% | 42.25% |
| Earnings before Tax (EBT) 1 | 10.7 | 16.49 | 19.46 | 17.69 | 24.1 | 34.7 |
| Net income 1 | 15.08 | 14.01 | 17.22 | 14.32 | 20.58 | 26.7 |
| Net margin | 46.03% | 36.28% | 32.48% | 25.27% | 30.19% | 35.36% |
| EPS 2 | 1.880 | 1.740 | 2.120 | 1.790 | 2.630 | 3.400 |
| Free Cash Flow | - | 14.36 | 15.74 | - | - | - |
| FCF margin | - | 37.19% | 29.68% | - | - | - |
| FCF Conversion (EBITDA) | - | 85.5% | 78.4% | - | - | - |
| FCF Conversion (Net income) | - | 102.49% | 91.38% | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 3/1/21 | 2/28/22 | 3/21/23 | 3/5/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.99 | 11.54 | 14.02 | 14.83 | 14.05 | 13.79 | 18.21 | 18.6 | 16.32 | 15.06 | 21.4 | 21 | 17.5 | 15.7 |
| EBITDA 1 | 5.413 | 1.868 | 4.097 | 5.332 | 4.62 | 3.743 | 6.385 | 7.33 | 6.459 | 2.682 | 9.9 | 9.5 | 7.4 | 5.9 |
| EBIT 1 | 5.253 | 1.71 | 3.942 | 5.178 | 4.467 | 3.616 | 6.256 | 7.18 | 6.299 | 2.522 | 9.7 | 9.3 | 7.2 | 5.7 |
| Operating Margin | 37.55% | 14.82% | 28.12% | 34.92% | 31.8% | 26.21% | 34.36% | 38.59% | 38.61% | 16.75% | 45.33% | 44.29% | 41.14% | 36.31% |
| Earnings before Tax (EBT) 1 | 5.257 | 1.706 | 3.943 | 5.191 | 4.601 | 3.956 | 6.633 | 7.666 | 6.988 | 2.814 | 10.4 | 10.1 | 7.9 | 6.4 |
| Net income 1 | 4.15 | 1.507 | 3.36 | 4.074 | 3.675 | 3.216 | 4.969 | 5.879 | 5.514 | 4.221 | 8 | 7.8 | 6.1 | 4.9 |
| Net margin | 29.66% | 13.06% | 23.97% | 27.48% | 26.16% | 23.31% | 27.29% | 31.6% | 33.8% | 28.04% | 37.38% | 37.14% | 34.86% | 31.21% |
| EPS 2 | 0.5100 | 0.1800 | 0.4100 | 0.5100 | 0.4600 | 0.4100 | 0.6300 | 0.7500 | 0.7100 | 0.5500 | 1.030 | 0.9900 | 0.7700 | 0.6200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/1/21 | 2/28/22 | 5/2/22 | 8/2/22 | 11/1/22 | 3/21/23 | 5/10/23 | 8/10/23 | 11/9/23 | 3/5/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | 37.3 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 14.4 | 15.7 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | 3.690 | 5.600 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 1.06 | 0.32 | - | - | - |
| Capex / Sales | - | 2.75% | 0.6% | - | - | - |
| Announcement Date | 3/3/20 | 3/1/21 | 2/28/22 | 3/21/23 | 3/5/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
26.11
USD
Average target price
65
USD
Spread / Average Target
+148.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.05% | 184M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.01B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- SMLR Stock
- Financials Semler Scientific, Inc.
